Avanir Pharmaceuticals Reports Fiscal 2012 Second Quarter Financial and Business Results - Yahoo Finance
25 May 2012, 7:46 pm
NUEDEXTA is contraindicated in patients concomitantly taking: QT-prolonging drugs metabolized by CYP2D6 (e.g., thioridazine and pimozide); monoamine oxidase inhibitors (MAOIs) within the preceding or following 14 days; other drugs containing ...

R&D Trends: Depression - Clinical attrition driven by mature market conditions - International Business Times
24 May 2012, 6:04 am
http://www.reportlinker.com/p0799259/RD-Trends-Depression-–-Clinical-attrition-driven-by-mature-market-conditions.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology OVERVIEWCatalystSummaryEXECUTIVE SUMMARYStrategic scoping and ...

Oryzon Nominates Specific LSD1 Inhibitor as Drug Candidate to Enter Preclinical Development in Acute Leukemia and Other Hematological Cancers - PRWeb
24 May 2012, 1:54 am
Recently, the company announced its decision to enter in preclinical development with its first drug candidate, a first-in-class bispecific Lysine Specific Demethylase 1 (LSD1) and monoamine oxidase B (MAO-B) inhibitor for the treatment of Huntington disease (HD).

Using Colonoscopy to Predict Parkinson’s Disease? - Medagadget.com
17 May 2012, 5:40 pm
Early diagnosis of Parkinson’s enables the disease to be treated with drugs such as dopamine agonists and monoamine oxidase type-B inhibitors, which can alleviate the condition’s symptoms and postpone the need to begin levodopa therapy.

Phase 3 Data Show NUCYNTA ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) - Phramalive.com
17 May 2012, 1:22 pm
NUCYNTA® ER is contraindicated in patients who are receiving monoamine oxidase inhibitors (MAOIs) or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels, which may result in adverse cardiovascular events.

Avraham Pharmaceuticals Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI - Phramalive.com
17 May 2012, 11:20 am
Ladostigil is a novel cholinesterase and brain-selective monoamine oxidase inhibitor, and neuroprotective agent for the treatment of Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases. The drug, which was exclusively ...

Cancer Tools Help Roche Push Ahead With Alzheimer’s Drug - Bloomberg
12 May 2012, 6:57 pm
By taking the drug back, Roche gave itself a candidate that doesn’t go after beta amyloid, he said. Instead it targets monoamine oxidase type B, or MAO-B, an enzyme that breaks down dopamine in the brain and contributes to the production of free radicals.